Media coverage about Mylan N.V. (NASDAQ:MYL) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mylan N.V. earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.3354213375553 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
- Theravance Biopharma (TBPH) and Mylan (MYL) Submit NDA to FDA for Revefenacin in Adults with COPD (streetinsider.com)
- Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease (finance.yahoo.com)
- Mylan to delist from Tel Aviv Stock Exchange February 12 (seekingalpha.com)
- Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE) (finance.yahoo.com)
- Overactive Bladder Treatment Market: Astellas Pharma, Pfizer, Allergan, Medtronic Plc, Mylan N.V (marketwatch.com)
Shares of Mylan N.V. (NASDAQ MYL) opened at $37.85 on Wednesday. The company has a market cap of $20,153.91, a price-to-earnings ratio of 7.99, a P/E/G ratio of 2.06 and a beta of 1.38. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $45.87.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. Mylan N.V. had a net margin of 7.28% and a return on equity of 20.63%. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.38 EPS. equities analysts expect that Mylan N.V. will post 4.56 EPS for the current year.
A number of equities research analysts recently commented on the stock. Citigroup Inc. set a $42.00 target price on shares of Mylan N.V. and gave the company a “buy” rating in a research report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. UBS AG restated a “buy” rating and set a $46.00 price target (down previously from $50.00) on shares of Mylan N.V. in a research note on Thursday, August 10th. BidaskClub upgraded shares of Mylan N.V. from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Finally, Instinet restated a “buy” rating and set a $37.00 price target on shares of Mylan N.V. in a research note on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $41.49.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.